Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Involvement of the JAK-STAT Pathway in the Molecular Landscape of Fusion-Free Myeloid Neoplasms with Eosinophilia

Blood (2023) 142 (Supplement 1): 78.

https://doi.org/10.1182/blood-2023-181250

Published: 2023

Journal Articles

Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy

Blood (2021) 138 (7): 507–519.

https://doi.org/10.1182/blood.2021011103

Published: 2021

Includes: Supplemental data

Journal Articles

Germline PAX5 mutation predisposes to familial B-cell precursor acute lymphoblastic leukemia

Blood (2021) 137 (10): 1424–1428.

https://doi.org/10.1182/blood.2020005756

Published: 2021

Includes: Supplemental data

Journal Articles

High frequency of clonal hematopoiesis in Erdheim-Chester disease

Fleur Cohen Aubart, Damien Roos-Weil, Marine Armand, Alice Marceau-Renaut, Jean-François Emile, Nicolas Duployez, Frédéric Charlotte, Stéphanie Poulain, Raphael Lhote, Zofia Hélias-Rodzewicz, Véronique Della-Valle, Olivier Bernard, Karim Maloum, Florence Nguyen-Khac, Jean Donadieu, Zahir Amoura, Omar Abdel-Wahab, Julien Haroche

Blood (2021) 137 (4): 485–492.

https://doi.org/10.1182/blood.2020005101

Published: 2021

Includes: Supplemental data

Journal Articles

Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia

Blood (2020) 135 (8): 542–546.

https://doi.org/10.1182/blood.2019003471

Published: 2020

Includes: Supplemental data

Journal Articles

Inherited transmission of the CSF3R T618I mutational hotspot in familial chronic neutrophilic leukemia

Nicolas Duployez, Christophe Willekens, Isabelle Plo, Alice Marceau-Renaut, Stéphane de Botton, Laurène Fenwarth, Thomas Boyer, Guillemette Huet, Olivier Nibourel, Christian Rose, Brigitte Nelken, Bruno Quesnel, Claude Preudhomme

Blood (2019) 134 (26): 2414–2416.

https://doi.org/10.1182/blood.2019003206

Published: 2019

Includes: Supplemental data

Journal Articles

A Single Center Experience of Cladribine, Cytarabine, Filgrastim and Mitoxantrone (CLAG-M regimen) in High-Risk or Relapsed/Refractory, Acute Myeloid Leukemia (AML)

Valérie Vidal, Laila Hamri, Alice Marceau-Renaut, Flore Sicre De Fontbrune, MD PhD, Virginie Eclache, Nevine Osman, Benjamin Papoular, Daniel Lusina, Sabine Brechignac, Regis Peffault De Latour, Claude Preudhomme, Claude Gardin, Thorsten Braun, MD PhD

Blood (2018) 132 (Supplement 1): 4007.

https://doi.org/10.1182/blood-2018-99-117237

Published: 2018

Journal Articles

Oncogenic Predictors of Outcome in Older AML Patients Treated Intensively. Analysis of the ALFA-1200 Trial

Blood (2018) 132 (Supplement 1): 993.

https://doi.org/10.1182/blood-2018-99-111144

Published: 2018

Journal Articles

Number of Mutations and Type of Prior Myeloproliferative Neoplasm Are Prognostic Factors in Acute Myeloid Leukemia Post Myeloproliferative Neoplasms

Edmond Chiche, Sarah Bonnet, Sarah Bertoli, MD PhD, Andrew T Kuykendall, MD, Lauris Gastaud, Pascal Boulay, Veronique De Mas, Eric Delabesse, MD PhD, Alice Marceau-Renaut, Claude Preudhomme, Anne Murati, David A Sallman, MD, S. Dominique Raynaud, MD, Christian Recher, MD PhD, Norbert Vey, MD PhD, Thomas Cluzeau, MD PhD

Blood (2018) 132 (Supplement 1): 2806.

https://doi.org/10.1182/blood-2018-99-114428

Published: 2018

Journal Articles

Clonal interference of signaling mutations worsens prognosis in core-binding factor acute myeloid leukemia

Raphael Itzykson, Nicolas Duployez, Annette Fasan, Gauthier Decool, Alice Marceau-Renaut, Manja Meggendorfer, Eric Jourdan, Arnaud Petit, Hélène Lapillonne, Jean-Baptiste Micol, Pascale Cornillet-Lefebvre, Norbert Ifrah, Guy Leverger, Hervé Dombret, Nicolas Boissel, Torsten Haferlach, Claude Preudhomme

Blood (2018) 132 (2): 187–196.

https://doi.org/10.1182/blood-2018-03-837781

Published: 2018

Includes: Supplemental data

Journal Articles

Clonal Interference of Signaling Mutations Holds Prognostic Relevance in Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)

Raphael Itzykson, MD PhD, Nicolas Duployez, PharmD, PhD, Annette Fasan, PhD, Alice Marceau-Renaut, PharmD, Manja Meggendorfer, PhD, Eric Jourdan, MD, Arnaud Petit, MD PhD, Hélène Lapillonne, MD PhD, Jean-Baptiste Micol, MD PhD, Pascale Cornillet-Lefebvre, Norbert Ifrah, MD, Guy Leverger, MD PhD, Herve Dombret, MD, Nicolas Boissel, MD PhD, Torsten Haferlach, MD, Claude Preudhomme, PharmD, PhD

Blood (2017) 130 (Supplement 1): 26.

https://doi.org/10.1182/blood.V130.Suppl_1.26.26

Published: 2017

Journal Articles

Clonal Hematopoiesis in Erdheim-Chester Disease

Julien Haroche, MD PhD, Stéphanie Poulain, MD PhD, Alice Marceau-Renaut, PharmD, Aline Renneville, Catherine Settegrana, Karim Maloum, Damien Roos-Weil, Florence Nguyen-Khac, MD PhD, Jean Donadieu, MD, Jean-François Emile, MD PhD, Zahir Amoura, Fleur Cohen-Aubart, MD PhD

Blood (2017) 130 (Supplement 1): 3788.

https://doi.org/10.1182/blood.V130.Suppl_1.3788.3788

Published: 2017

Journal Articles

Clofarabine-Based Consolidation Improves Relapse-Free Survival of Patients with Acute Myeloid Leukemia with Complex or Micro-Complex Karyotype: Results from the Randomized ALFA-0702 Study

Laurène Fenwarth, MSc, MD, Nicolas Duployez, PharmD, PhD, Xavier Thomas, MD, Nicolas Boissel, MD PhD, Sandrine Geffroy, PhD, Alice Marceau-Renaut, PharmD, Denis Caillot, MD, Emmanuel Raffoux, MD, Emilie Lemasle, MD, Jean-Pierre Marolleau, MD PhD, Céline Berthon, MD PhD, Meyling H. Cheok, MSPharm, PhD, Pauline Peyrouze, Arnaud Pigneux, MD PhD, Norbert Vey, Karine Celli-Lebras, CRA, Christine Terré, PharmD, PhD, Claude Preudhomme, PharmD, PhD, Herve Dombret, MD

Blood (2017) 130 (Supplement 1): 465.

https://doi.org/10.1182/blood.V130.Suppl_1.465.465

Published: 2017

Journal Articles

Molecular Profiling Defines Distinct Prognostic Subgroups in Chilhood Acute Myeloid Leukemia: A Report from the French ELAM02 Study Group

Blood (2017) 130 (Supplement 1): 403.

https://doi.org/10.1182/blood.V130.Suppl_1.403.403

Published: 2017

Journal Articles

Early Detection of WT1 minimal Residual Disease Predicts Outcome in Acute Myeloid Leukemia and Identify Patients with High Risk of Relapse Independently of Allogeneic Stem Cell Transplantation

Juliette Lambert, Jérôme Lambert, MDPhD, Xavier Thomas, MD, Alice Marceau-Renaut, PharmD, Aline Renneville, MDPhD, Marie-Magdelaine Coude, MD, Sandrine Hayette, MD, Christian Recher, MD PhD, Emmanuel Raffoux, MD, Arnaud Pigneux, MD PhD, Céline Berthon, MD PhD, Christine Terré, PharmD, PhD, Karine Celli-Lebras, CRA, Sylvie Castaigne, MD, Nicolas Boissel, MD PhD, Philippe Rousselot, Herve Dombret, MD, Claude Preudhomme, PharmD, PhD

Blood (2017) 130 (Supplement 1): 29.

https://doi.org/10.1182/blood.V130.Suppl_1.29.29

Published: 2017

Journal Articles

Genomic Landscape and Prognosis in Pediatric Acute Myeloid Leukemia: A Study on the French ELAM02 Trial

Blood (2016) 128 (22): 1676.

https://doi.org/10.1182/blood.V128.22.1676.1676

Published: 2016

Journal Articles

Comprehensive mutational profiling of core binding factor acute myeloid leukemia

Blood (2016) 127 (20): 2451–2459.

https://doi.org/10.1182/blood-2015-12-688705

Published: 2016

Includes: Supplemental data

Journal Articles

Inversely to DNMT3A, IDH1/IDH2 Are Good Targets for Monitoring Minimal Residual Disease (MRD) in Acute Myeloid Leukemia (AML): A Pilot Study of the ALFA Group

Blood (2014) 124 (21): 2327.

https://doi.org/10.1182/blood.V124.21.2327.2327

Published: 2014

Journal Articles

Absolute Quantification of EVI1 Overexpression in Acute Myeloid Leukemia By RQ-PCR Analysis : A Study of the ALFA Group

Thomas Smol, Aline Renneville, Olivier Nibourel, Alice Marceau-Renaut, Karine Celli-Lebras, Céline Berthon, Bruno Quesnel, MD PhD, Nicolas Boissel, MD PhD, Christine Terré, Xavier Thomas, Sylvie Castaigne, Hervé Dombret, MD PhD, Claude Preudhomme, PharmD, PhD

Blood (2014) 124 (21): 1062.

https://doi.org/10.1182/blood.V124.21.1062.1062

Published: 2014

Journal Articles

Genomic Landscape of Pediatric CBF-AML By SNP-Array Karyotyping and Extensive Mutational Analysis

Blood (2014) 124 (21): 1007.

https://doi.org/10.1182/blood.V124.21.1007.1007

Published: 2014

NARROW

Involvement of the JAK-STAT Pathway in the Molecular Landscape of Fusion-Free Myeloid Neoplasms with Eosinophilia

Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy

Germline PAX5 mutation predisposes to familial B-cell precursor acute lymphoblastic leukemia

High frequency of clonal hematopoiesis in Erdheim-Chester disease

Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia

Inherited transmission of the CSF3R T618I mutational hotspot in familial chronic neutrophilic leukemia

A Single Center Experience of Cladribine, Cytarabine, Filgrastim and Mitoxantrone (CLAG-M regimen) in High-Risk or Relapsed/Refractory, Acute Myeloid Leukemia (AML)

Oncogenic Predictors of Outcome in Older AML Patients Treated Intensively. Analysis of the ALFA-1200 Trial

Number of Mutations and Type of Prior Myeloproliferative Neoplasm Are Prognostic Factors in Acute Myeloid Leukemia Post Myeloproliferative Neoplasms

Clonal interference of signaling mutations worsens prognosis in core-binding factor acute myeloid leukemia

Clonal Interference of Signaling Mutations Holds Prognostic Relevance in Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)

Clonal Hematopoiesis in Erdheim-Chester Disease

Clofarabine-Based Consolidation Improves Relapse-Free Survival of Patients with Acute Myeloid Leukemia with Complex or Micro-Complex Karyotype: Results from the Randomized ALFA-0702 Study

Molecular Profiling Defines Distinct Prognostic Subgroups in Chilhood Acute Myeloid Leukemia: A Report from the French ELAM02 Study Group

Early Detection of WT1 minimal Residual Disease Predicts Outcome in Acute Myeloid Leukemia and Identify Patients with High Risk of Relapse Independently of Allogeneic Stem Cell Transplantation

Genomic Landscape and Prognosis in Pediatric Acute Myeloid Leukemia: A Study on the French ELAM02 Trial

Comprehensive mutational profiling of core binding factor acute myeloid leukemia

Inversely to DNMT3A, IDH1/IDH2 Are Good Targets for Monitoring Minimal Residual Disease (MRD) in Acute Myeloid Leukemia (AML): A Pilot Study of the ALFA Group

Absolute Quantification of EVI1 Overexpression in Acute Myeloid Leukemia By RQ-PCR Analysis : A Study of the ALFA Group

Genomic Landscape of Pediatric CBF-AML By SNP-Array Karyotyping and Extensive Mutational Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only